Previous 10 | Next 10 |
Gamida Cell Ltd (GMDA) Q3 2020 Earnings Conference Call November 10, 2020, 08:30 ET Company Participants Joshua Hamermesh - Chief Business Officer Julian Adams - CEO & Director Ronit Simantov - Chief Medical Officer Shai Lankry - CFO Michele Korfin - Chief Operating & Chief Commercial...
Gamida Cell (GMDA): Q3 GAAP EPS of -$0.98 misses by $0.67.Cash and cash equivalents of $73.3MPress Release For further details see: Gamida Cell EPS misses by $0.67
– Primary and secondary endpoints were met in Phase 3 study of omidubicel in patients with hematologic malignancies who underwent a bone marrow transplant – – Full data from Phase 3 study of omidubicel in patients with hematologic malignancies anticipated ...
– Updated data from Phase 1 Study of GDA-201 to be presented during an oral session – – New data on omidubicel in patients with severe aplastic anemia will also be presented – Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and imm...
Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that Julian Adams, Ph. D., chief executive officer of Gamida Cell, will present at the H.C. Wainwright 6 th Annual Israel Conference...
Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a conference call and live audio webcast on Tuesday, November 10, 2020, at 8:30 a.m. ET to review its...
Gamida Cell recently executed a secondary at $4.50 a share on the back of positive Phase 3 clinical data for its lead asset. The cell therapy biotech now trades at half its 2018 post IPO price despite a likely approval and launch of omidubicel in 2021. The stock seems undervalued ...
– Organizations to work together to integrate Be The Match BioTherapies’ existing cell therapy infrastructure to manage the supply chain for potential commercialization of omidubicel – Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune th...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week aheadBig banks will lead off the Q3 earnings season next week with investors likely to see more surprises than normal due to t...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
News, Short Squeeze, Breakout and More Instantly...
Gamida Cell Ltd. Company Name:
GMDA Stock Symbol:
NASDAQ Market:
CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney d...
2024-04-03 06:21:00 ET How to Analyze Different Penny Stocks Sectors to Make Money Investing in penny stocks offers an accessible entry point for individuals aiming to participate in the stock market with a lower initial investment. Analyzing different sectors within the realm of penn...
A look at the top 10 most actives in the United States Trio Petroleum Corp. (TPET) rose 43.8% to $0.1485 on volume of 202,621,744 shares Nikola Corporation (NKLA) fell 5.5% to $0.9736 on volume of 187,304,976 shares C3is Inc. (CISS) rose 13.3% to $0.0409 on volume of 136,767,990 shares ...